keyword
https://read.qxmd.com/read/38534761/genetic-signatures-for-distinguishing-chemo-sensitive-from-chemo-resistant-responders-in-prostate-cancer-patients
#1
JOURNAL ARTICLE
Lemohang Gumenku, Mamello Sekhoacha, Beynon Abrahams, Samson Mashele, Aubrey Shoko, Ochuko L Erukainure
Prostate cancer remains a significant public health concern in sub-Saharan Africa, particularly impacting South Africa with high mortality rates. Despite many years of extensive research and significant financial expenditure, there has yet to be a definitive solution to prostate cancer. It is not just individuals who vary in their response to treatment, but even different nodules within the same tumor exhibit unique transcriptome patterns. These distinctions extend beyond mere differences in gene expression levels to encompass the control and networking of individual genes...
March 11, 2024: Current Issues in Molecular Biology
https://read.qxmd.com/read/38523897/real-world-prostate-specific-antigen-reduction-and-survival-outcomes-of-metastatic-hormone-sensitive-prostate-cancer-patients-treated-with-apalutamide-an-observational-retrospective-and-multicentre-study
#2
JOURNAL ARTICLE
Alicia López-Abad, Miguel Ramírez Backhaus, Gerardo Server Gómez, Enrique Cao Avellaneda, Cristóbal Moreno Alarcón, Pedro López Cubillana, Pablo Yago Giménez, Pedro de Pablos Rodríguez, María J Juan Fita, Miguel Á Climent Durán, Iris Guardiola Ruiz, Natalia Vidal Crespo, Miriam Artés Artés, Raúl Montoya Chinchilla, Juan Moreno Avilés, Pablo L Guzmán Martínez-Valls, Pedro Á López González
BACKGROUND: Metastatic hormone-sensitive prostate cancer (mHSPC) treatment has changed drastically during the last years with the emergence of androgen receptor-targeted agents (ARTAs). ARTA combined with androgen deprivation therapy has demonstrated better oncological and survival outcomes in these patients. However, the optimal choice among different ARTAs remains uncertain due to their analogous efficacy. OBJECTIVES: The objective of this study was to describe prostate-specific antigen (PSA) response and oncological outcomes of patients with mHSPC treated with apalutamide...
March 2024: Prostate International
https://read.qxmd.com/read/38523017/three-and-seven-month-prostate-specific-antigen-levels-as-prognostic-markers-for-overall-survival-in-metastatic-hormone-sensitive-prostate-cancer-results-from-swog-s1216-a-phase-3-randomized-trial-of-androgen-deprivation-plus-orteronel-or-bicalutamide
#3
JOURNAL ARTICLE
Mamta Parikh, Catherine Tangen, Maha H A Hussain, Shilpa Gupta, Sam Callis, Yeonjung Jo, Andrea Harzstark, Channing J Paller, Saby George, Matthew R Zibelman, Heather H Cheng, Benjamin L Maughan, Jingsong Zhang, Russell K Pachynski, Alan H Bryce, Daniel W Lin, David I Quinn, Seth P Lerner, Ian M Thompson, Tanya B Dorff, Primo N Lara, Neeraj Agarwal
BACKGROUND: A robust decrease in prostate-specific antigen (PSA) in response to androgen deprivation therapy (ADT) has been evaluated as a prognostic factor in patients with metastatic hormone-sensitive prostate cancer (mHSPC) since 2006, but the treatment of mHSPC has since evolved to include intensified therapy. OBJECTIVE: We assessed the association of PSA levels at 3 (PSA-3mo) and 7 (PSA-7mo) mo with overall survival (OS) in patients with mHSPC treated with ADT combined with either bicalutamide or orteronel in the S1216 phase 3 clinical trial...
March 23, 2024: European Urology Oncology
https://read.qxmd.com/read/38522838/clinical-implementation-of-a-non-invasive-multi-analyte-ddpcr-test-to-screen-for-androgen-receptor-alterations
#4
JOURNAL ARTICLE
Regina Stitz, Franz Stoiber, Renè Silye, Georgios Vlachos, Silvia Andaloro, Elisabeth Rebhan, Michael Dunzinger, Franz Pühringer, Caroline Gallo, Amin El-Heliebi, Ellen Heitzer, Cornelia Hauser-Kronberger
Recent studies have shown that alterations of the androgen receptor (AR) are associated with resistance to AR-directed therapy in prostate cancer. Thus, it is crucial to develop robust detection methods for AR alterations as predictive biomarkers to enable applicability in clinical practice. We designed and validated five multiplex droplet digital PCR (ddPCR) assays for reliable detection of 12 AR targets including AR amplification, AR-V7 and 10 AR hotspot mutations as well as AR and KLK3 gene expression from plasma derived cell-free (cf)DNA and cfRNA...
March 22, 2024: Journal of Molecular Diagnostics: JMD
https://read.qxmd.com/read/38501452/acetylated-khsrp-impairs-dna-damage-response-related-mrna-decay-and-facilitates-prostate-cancer-tumorigenesis
#5
JOURNAL ARTICLE
Haihua Yuan, Renjie Cai, Biying Chen, Qian Wang, Mengting Wang, Junyi An, Weishu An, Ye Tao, Jianxiu Yu, Bin Jiang, Yanjie Zhang, Ming Xu
Androgen-regulated DNA damage response (DDR) is one of the essential mechanisms in prostate cancer (PCa), a hormone-sensitive disease. The heterogeneous nuclear ribonucleoprotein K (hnRNPK)-homology splicing regulatory protein known as far upstream element-binding protein 2 (KHSRP) is an RNA-binding protein that can attach to AU-rich elements in the 3' untranslated region (3'-UTR) of messenger RNAs (mRNAs) to mediate mRNA decay and emerges as a critical regulator in the DDR to preserve genome integrity...
March 19, 2024: Molecular Oncology
https://read.qxmd.com/read/38500864/neoadjuvant-chemohormonal-therapy-before-radical-prostatectomy-in-high-risk-prostate-cancer-a-mini-review
#6
REVIEW
Junjie Fan, Zhangdong Jiang, Guojing Wang, Dalin He, Kaijie Wu
High-risk localized prostate cancer (PCa) has the potential of recurrence and progression to a lethal phenotype, and neoadjuvant therapy followed by radical prostatectomy (RP) may be an option for these patients. Docetaxel has been recently shown to be an effective chemotherapeutic agent for high-volume metastatic hormone-sensitive PCa and metastatic castration-resistant PCa, and these increased efficacy create the impetus to assess the potential role of preoperative docetaxel in high-risk localized PCa. In this mini-review, we found that neoadjuvant chemohormonal therapy (NCHT) may be an effective neoadjuvant regimen to improve oncological outcome of high-risk PCa...
2024: American Journal of Clinical and Experimental Urology
https://read.qxmd.com/read/38494380/systemic-and-tumor-directed-therapy-for-oligorecurrent-metastatic-prostate-cancer-saturn-primary-endpoint-results-from-a-phase-2-clinical-trial
#7
JOURNAL ARTICLE
John Nikitas, Matthew Rettig, John Shen, Robert Reiter, Alan Lee, Michael L Steinberg, Luca F Valle, Ankush Sachdeva, Tahmineh Romero, Jeremie Calais, Johannes Czernin, Nicholas G Nickols, Amar U Kishan
Nearly all men with metastatic hormone-sensitive prostate cancer treated with intermittent androgen deprivation therapy (ADT) experience recurrence within 6 mo of testosterone recovery. We conducted a single-arm phase 2 trial to evaluate whether addition of dual androgen receptor pathway inhibitors (ARPIs) and metastasis-directed stereotactic body radiotherapy (SBRT) to intermittent ADT improves recurrence rates for men with between one and five nonvisceral, extrapelvic metastases on prostate-specific membrane antigen positron emission tomography/computed tomography after prior radical prostatectomy...
March 16, 2024: European Urology
https://read.qxmd.com/read/38493067/feasibility-of-next-generation-sequencing-of-liquid-biopsy-circulating-tumor-dna-samples-and-tumor-tissue-from-patients-with-metastatic-prostate-cancer-in-a-real-world-clinical-setting-in-germany
#8
JOURNAL ARTICLE
Philipp Mandel, Benedikt Hoeh, Clara Humke, Claudia Doering, Mike Wenzel, Cristina Cano Garcia, Nina Fuhr, Florestan Koll, Anne Fassl, Derya Tilki, Thomas Steuber, Iris Faull, Jan Jeroch, Silvana Ebner, Christina Schmitt, Henning Reis, Jens Köllermann, Konstantinos D Kokkaliaris, Melanie C Demes, Felix K H Chun, Peter J Wild
BACKGROUND AND OBJECTIVE: With European Medicines Agency approval of PARP inhibitors in metastatic castration-resistant prostate cancer and ongoing trials in metastatic hormone-sensitive prostate cancer, detection of genetic alterations in BRCA1/2 and other homologous recombination repair genes has gained an important role. Our aim was to investigate the feasibility and comparability of comprehensive next-generation sequencing (NGS) of liquid biopsy (LB; circulating tumor DNA) and tumor tissue (TT) samples in a real-world clinical setting...
March 15, 2024: European Urology Focus
https://read.qxmd.com/read/38491294/association-between-thyroid-disorders-and-extra-thyroidal-cancers-a-review
#9
REVIEW
Xin Jia, Jingru Li, Zongliang Jiang
Thyroid hormone has been shown to have both tumor-promoting and tumor-suppressing actions, which has led to significant debate over its involvement in the development of cancer. Proliferation, apoptosis, invasiveness, and angiogenesis are all aspects of cancer that are affected by the thyroid hormones T3 and T4, according to research conducted in animal models and in vitro experiments. The effects of thyroid hormones on cancer cells are mediated by many non-genomic mechanisms, one of which involves the activation of the plasma membrane receptor integrin αvβ3...
March 15, 2024: Clinical & Translational Oncology
https://read.qxmd.com/read/38481910/remission-depth-in-metastatic-hormone-sensitive-prostate-cancer-is-associated-with-prognosis-in-patients-with-initial-prostate-specific-antigen-values-above-100-ng-ml
#10
JOURNAL ARTICLE
Takeshi Azuma, Akimasa Katsumata, Masato Kano, Koji Tsumura
INTRODUCTION: Recently, new drugs have caused a paradigm shift in the treatment of metastatic hormone-sensitive prostate cancer (HSPC). Meanwhile, research has identified several prognostic factors of metastatic HSPC. OBJECTIVE: The present study focused on remission depth in metastatic HSPC and evaluated its association with remission depth. METHOD: We analyzed 427 patients diagnosed with metastatic HSPC with serum initial prostate-specific antigen (PSA) > 100 ng/ml...
February 2024: Curēus
https://read.qxmd.com/read/38481666/testosterone-nadir-and-clinical-outcomes-in-patients-with-advanced-prostate-cancer-post-hoc-analysis-of-triptorelin-pamoate-phase-iii-studies
#11
JOURNAL ARTICLE
Laurence Klotz, Tri Tat
OBJECTIVE: The objective of the study is to evaluate whether low nadir testosterone during treatment with triptorelin pamoate, a luteinising hormone-releasing hormone (LHRH) agonist, is associated with improved clinical outcomes in patients with advanced prostate cancer using a retrospective analysis of clinical trial data. PATIENTS AND METHODS: Data were pooled from three prospective, 9-12-month Phase III studies of triptorelin monotherapy in patients with advanced prostate cancer (including NCT00751790)...
March 2024: BJUI compass
https://read.qxmd.com/read/38479871/treatment-outcomes-of-second-line-systemic-therapy-for-neuroendocrine-prostate-cancer-a-report-of-four-cases
#12
JOURNAL ARTICLE
Yuto Tsubonuma, Keita Funakoshi, Tomohisa Takaba, Kazumasa Jyojima, Akinori Minato, Ikko Tomisaki, Kenichi Harada, Naohiro Fujimoto
Neuroendocrine prostate cancer (NEPC) is a histological variant of prostate cancer and is characterized by aggressiveness and poor clinical outcomes. NEPC usually develops as a mechanism of treatment resistance in patients receiving hormone therapy for advanced prostate cancer. NEPC is sensitive to primary platinum-based chemotherapy, and has a short response duration. Second-line therapy is required in many cases, but clinical data on subsequent treatment after progression to first-line chemotherapy is limited...
2024: Journal of UOEH
https://read.qxmd.com/read/38462772/management-of-cancer-treatment-induced-bone-loss-in-patients-with-breast-and-hormone-sensitive-prostate-cancer-aiom-survey
#13
JOURNAL ARTICLE
Anna Amela Valsecchi, Vittorio Fusco, Massimo Di Maio, Daniele Santini, Marcello Tucci, Ugo De Giorgi, Rossana Dionisio, Francesca Vignani, Saverio Cinieri
PURPOSE: Cancer treatment-induced bone loss is a side effect of hormonal therapy that can severely affect patients' quality of life. The aim of this survey was to obtain an updated picture of management of bone health in patients with breast cancer undergoing adjuvant hormonal therapy and in patients with hormone sensitive prostate cancer according to Italian oncologists. METHODS: Our survey was made up of 21 multiple-choice questions: the first part dealt with the respondents' characteristics, while the second with management of bone health in the described setting...
March 10, 2024: Tumori
https://read.qxmd.com/read/38452035/a-phase-ii-study-of-rucaparib-monotherapy-in-nonmetastatic-hormone-sensitive-prostate-cancer-demonstrating-brcaness-genotype-roar
#14
JOURNAL ARTICLE
Kamal Kant Sahu, Haoran Li, Vinay Mathew Thomas, Mallory Benson, Ken Boucher, Sumati Gupta, Manish Kohli, Umang Swami, Neeraj Agarwal, Benjamin L Maughan
BACKGROUND: Both germline and somatic BReast CAncer gene (BRCA) mutations are poor prognostic markers in men with localized or metastatic prostate cancer. For instance, men with these mutations often are diagnosed with prostate cancer earlier and develop metastatic disease earlier compared with those who do not harbor similar mutations. Patients with germline alterations typically have more advanced disease and shorter overall survival (Castro E, Goh C, Olmos D, et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer...
March 7, 2024: Oncologist
https://read.qxmd.com/read/38447942/-role-of-bone-scan-index-bsi-in-the-prognosis-and-treatment-efficacy-in-castration-sensitive-prostate-cancer-patients-with-bone-metastasis
#15
JOURNAL ARTICLE
Kaho Deguchi, Takeshi Sasaki, Hiroyuki Oue, Takashi Okamoto, Momoko Kato, Shinya Kajiwara, Shinichiro Higashi, Satoru Masui, Kouhei Nishikawa, Takahiro Inoue
Bone is the most common metastatic site in prostate cancer (PCa). Although the extent of disease (EOD) grade is used for evaluating burden of bone metastasis, the accuracy of bone metastasis classification needs improvement. Bone scan index (BSI) was developed as a quantitative tool to enhance the interpretability and clinical relevance of the bone scan. This study aimed to explore the role of BSI using BONENAVI® software in determining the prognosis and treatment efficacy in castration-sensitive PCa (mCSPC) patients with bone metastasis...
February 2024: Hinyokika Kiyo. Acta Urologica Japonica
https://read.qxmd.com/read/38445371/optimal-systemic-therapy-in-men-with-low-volume-prostate-cancer
#16
JOURNAL ARTICLE
Akshat Saxena, Jack Andrews, Alan Haruo Bryce, Irbaz Bin Riaz
PURPOSE OF REVIEW: Low-volume prostate cancer is an established prognostic category of metastatic hormone-sensitive prostate cancer. However, the term is often loosely used to reflect the low burden of disease across different prostate cancer states. This review explores the definitions of low-volume prostate cancer, biology, and current evidence for treatment. We also explore future directions, including the impact of advanced imaging modalities, particularly prostate-specific membrane antigen (PSMA) positron emission tomography (PET) scans, on refining patient subgroups and treatment strategies for patients with low-volume prostate cancer...
March 6, 2024: Current Opinion in Urology
https://read.qxmd.com/read/38444678/lower-baseline-testosterone-level-is-related-to-earlier-development-of-castration-resistance-in-metastatic-prostate-cancer-a-multi-center-cohort-study
#17
JOURNAL ARTICLE
Ho Ming Chris Wong, Peter Ka-Fung Chiu, Ignacio Puche-Sanz, Zhao Xue, Dong-Ning Chen, Enrique Gomez-Gomez, Isabel Heidegger, Mona Kafka, Yong Wei, Shinichi Sakamoto, Anthony Chi Fai Ng
PURPOSE: In the era of concurrent combination therapy in metastatic hormone sensitive prostate cancer, the impact of the testosterone level before initiating androgen deprivation therapy on treatment outcome is still uncertain. We aimed to investigate its effect on time-to-castration-resistance in a metastatic hormone sensitive prostate cancer cohort. METHODS: This is a multi-center retrospective study of 5 databases from China, Japan, Austria and Spain including 258 metastatic hormone sensitive prostate cancer patients with androgen deprivation therapy initiated between 2002 and 2021...
2024: Frontiers in Oncology
https://read.qxmd.com/read/38440717/a-patient-with-oligometastatic-hormone-sensitive-prostate-cancer-who-achieved-long-term-progression-free-survival-following-cytoreductive-radical-prostatectomy-and-metastasectomy
#18
Daisuke Mamiya, Toshiki Kijima, Atsuko Takada-Owada, Hidetoshi Kokubun, Toshitaka Uematsu, Kohei Takei, Tsunehito Kambara, Kazuyuki Ishida, Hiroshi Taneichi, Takao Kamai
INTRODUCTION: Oligometastatic prostate cancer can be well-controlled through combined local and metastasis-directed therapies. However, the effects of cytoreductive radical prostatectomy and metastasectomy remain unclear. CASE PRESENTATION: A 52-year-old man presented with prostate cancer and isolated bone metastasis to the thoracic spine. Six months after neoadjuvant hormonal therapy, the patient underwent cytoreductive radical prostatectomy and total en bloc spondylectomy...
March 2024: IJU case reports
https://read.qxmd.com/read/38429210/development-and-independent-validation-of-a-prognostic-gene-expression-signature-based-on-rb1-pten-and-tp53-in-metastatic-hormone-sensitive-prostate-cancer-patients
#19
JOURNAL ARTICLE
Natalia Jiménez, Marta Garcia de Herreros, Òscar Reig, Mercedes Marín-Aguilera, Caterina Aversa, Laura Ferrer-Mileo, Samuel García-Esteve, Leonardo Rodríguez-Carunchio, Isabel Trias, Albert Font, Alejo Rodriguez-Vida, Miguel Ángel Climent, Sara Cros, Isabel Chirivella, Montserrat Domènech, Mariona Figols, Joan Carles, Cristina Suárez, Daniel Herrero Rivera, Enrique González-Billalabeitia, Claudia Cívico, Núria Sala-González, Vicenç Ruiz de Porras, Maria J Ribal, Aleix Prat, Begoña Mellado
BACKGROUND: Androgen deprivation therapy (ADT) with docetaxel (D) and/or antiandrogen receptor therapies (ARTs) are the standard therapies in metastatic hormone-sensitive prostate cancer (mHSPC). Alterations in the tumor suppressor genes (TSGs) RB1, PTEN, and TP53 are associated with an aggressive evolution and treatment resistance in castration-resistant prostate cancer (CRPC). OBJECTIVE: To study the clinical implications of TSG mRNA expression in mHSPC patients...
March 1, 2024: European Urology Oncology
https://read.qxmd.com/read/38426229/metastasis-directed-therapy-in-oligometastatic-prostate-cancer
#20
JOURNAL ARTICLE
Marcin Miszczyk, Timo Soeterik, Giancarlo Marra, Akihiro Matsukawa, Shahrokh F Shariat
PURPOSE OF REVIEW: To summarize the recent findings on the subject of metastasis-directed therapy (MDT) in the treatment of oligometastatic prostate cancer (omPCa). RECENT FINDINGS: Evidence from two randomized clinical trials (RCTs) and a meta-analysis show favorable toxicity profiles, and the potential to delay androgen-deprivation therapy (ADT) for up to two years in nearly half of patients with metachronous hormone-sensitive omPCa. Another RCT showed promising results of MDT as treatment-escalation method combined with androgen receptor signaling inhibitors (ARSI) in first-line treatment for castration-resistant omPCa...
March 1, 2024: Current Opinion in Urology
keyword
keyword
162680
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.